查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1497656

心臟 POC 测试市场：按产品类型、生物标记类型和最终用户 - 2024-2030 年全球预测

Cardiac Point of Care Testing Market by Product (Analyzers, Kits & Assays, Software & Services), Biomarker Type (Cardiac Troponins, CK-MB Fraction, D-Dimer), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年心臟POC检测市场规模为83.1亿美元，2024年达93.8亿美元，预计2030年将达到197.4亿美元，复合年增长率为13.14%。

心臟 POC 测试是指对心臟病患者进行床边或患者附近测试，有助于即时做出临床决策。这种形式的诊断测试是在传统实验室环境之外进行的，通常在患者护理时间和地点进行，例如急诊室、诊所、救护车服务和重症监护病房。心臟 POC 测试的主要目的是获得快速测试结果，可用于评估患者的心臟状态，以便及时、知情的治疗性介入。它通常用于检测与心臟事件相关的生物标记物，例如肌红蛋白、同型半胱氨酸和 Hs C 反应蛋白 (CRP)。在快速发展的医疗保健领域，由于对快速、准确的心血管诊断的需求不断增长，心臟护理点 (POC) 测试市场正在蓬勃发展。该市场的定义是设计、製造和销售易于使用的诊断设备和相应的反应剂，以促进现场心血管健康评估。这些设备可用于急诊环境，为包括医院、门诊诊所和家庭医疗保健在内的各种客户提供服务。心血管疾病在人群中的盛行率不断上升、技术进步有望提高诊断可靠性以及全球医疗保健投资的增加，推动了心臟 POC 测试的普及。然而，严格的法律规范、对诊断准确性的担忧以及新兴市场的财务限制等障碍正在阻碍全球心臟 POC 市场的扩张。心臟 POC 测试技术的改进和稳定发展，包括提高测试能力的设备和生物标誌物，为市场上的供应商提供了充满希望的机会。

主要市场统计
基准年[2023] 83.1亿美元
预测年份 [2024] 93.8亿美元
预测年份 [2030] 197.4亿美元
复合年增长率（%） 13.14%

区域洞察

在美洲，由于心血管疾病的流行、医疗成本的增加以及强大的医疗基础设施的存在，心臟 POC 测试市场继续稳定成长。此外，最尖端科技的采用、积极的政府倡议以及由于主要市场参与者的存在而提供的广泛产品正在推动成长。 EMEA（欧洲、中东和非洲）地区的市场格局充满活力，欧洲市场受益于有利的政府政策、大量老年人口以及旨在减轻心血管疾病负担的倡议。由于中东国家医疗保健投资增加以及非洲心臟健康意识不断增强，中东和非洲市场不断增长。亚太地区是心臟 POC 检测前景看好的市场，与美洲和欧洲、中东和非洲相比，预计成长率最高。这是由中国和印度等国家庞大的人口基数、快速发展的医疗基础设施以及不断增长的医疗支出所推动的。此外，包括心臟病文明病在该地区呈上升趋势，进一步增加了对快速高效诊断方法的需求。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在心臟 POC 测试市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对心臟 POC 测试市场中供应商的现状进行深入而详细的评估。对供应商贡献的彻底比较和分析可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在心臟 POC 测试市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群心血管疾病发生率增加
      • 政府对POC测试的积极推动介绍
      • 改善世界各地经济体的医疗保健支出
    • 抑制因素
      • 心臟 POC 测试中使用的材料和组件的成本变化
    • 机会
      • 心臟 POC 测试的改进和持续进步
      • 新生物标记物开发进展以提高检测能力
    • 任务
      • 心臟 POC 测试的操作和技术复杂性
  • 市场区隔分析
    • 产品：诊所对多重检测的需求增加
    • 生物标记类型：用于早期心臟检测的心臟型脂肪酸结合蛋白质（H-FABP）和缺血修饰白蛋白（IMA）的需求不断增加
    • 最终用户：在具有大样本量的复杂系统的诊断实验室中增加使用心臟 POC 测试
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章心臟 POC 测试市场：依产品

  • 分析仪
  • 套件和检测
  • 软体和服务

第七章按生物标记类型分類的心臟 POC 测试市场

  • 心肌肌钙蛋白
  • CK-MB分数
  • D-二聚体
  • 心型脂肪酸结合蛋白质（H-FABP）
  • 同型半胱氨酸
  • hs C 反应蛋白 (CRP)
  • 缺血修饰白蛋白 (IMA)
  • 肌红蛋白
  • 利尿钠胜肽(NP)
  • sCD40L

第 8 章 心臟 POC 测试市场：依最终用户分类

  • 诊断实验室
  • 医院/诊所
  • 研究/学术机构

第九章 美洲心臟POC测试市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太心臟POC测试市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲心臟POC测试市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Hipro照护现场诊断在印度推出
    • Jana Care 与罗氏合作开发和分销血液检测平台，以改善慢性肾臟病和心臟病患者的远距护理
    • Cipla 扩大诊断产品组合併推出就地检验设备
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-3F5063247F53

[183 Pages Report] The Cardiac Point of Care Testing Market size was estimated at USD 8.31 billion in 2023 and expected to reach USD 9.38 billion in 2024, at a CAGR 13.14% to reach USD 19.74 billion by 2030.

Cardiac point of care testing refers to the bedside or near-patient testing of cardiac patients that facilitates immediate clinical decision-making. This form of diagnostic testing is performed outside of traditional laboratory environments, typically at the time and place of patient care, such as in emergency departments, clinics, ambulance services, or critical care units. The primary goal of cardiac point of care testing is to obtain rapid test results that can be used to assess the condition of a patient's heart, enabling timely and informed treatment interventions. It is often utilized for the detection of biomarkers associated with cardiac events, including myoglobin, homocysteine, and hs C-reactive protein (CRP). In the rapidly advancing domain of healthcare, the cardiac point of care (POC) testing market is gaining momentum, driven by the escalating need for swift and precise cardiovascular diagnostics. This market is defined by the engineering, manufacturing, and commerce of user-friendly diagnostic instruments and their corresponding reactive agents that facilitate on-site cardiovascular health assessments. These devices, instrumental within acute medical scenarios, cater to a diverse clientele across hospitals, outpatient clinics, and home healthcare. The proliferation of cardiac point of care testing is driven by increasing incidences of cardiovascular diseases among the population, technological strides that promise enhanced diagnostic veracity, and rising global healthcare investment. Despite obstacles such as stringent regulatory frameworks, concerns over diagnostic accuracy, and financial limitations in developing health ecosystems hinder the scope of the global cardiac point of care market. Improvements and robust advancements in cardiac POC testing technologies, including devices and biomarkers to improve testing capabilities, portray promising opportunities for the market vendors.

KEY MARKET STATISTICS
Base Year [2023] USD 8.31 billion
Estimated Year [2024] USD 9.38 billion
Forecast Year [2030] USD 19.74 billion
CAGR (%) 13.14%

Regional Insights

In the Americas, the market for cardiac point of care testing continues to display robust growth, driven by the prevalence of cardiovascular diseases, rising healthcare expenditure, and the presence of robust healthcare infrastructure. Additionally, the growth is facilitated by the adoption of cutting-edge technologies, active government initiatives, and the availability of a wide range of products owing to the presence of significant market players. The EMEA region experiences a dynamic market landscape for cardiac point of care testing, where the European market benefits from favorable government policies, a high geriatric population, and an increasing number of initiatives aimed at lowering the burden of cardiovascular diseases. The Middle East and Africa showcase a growing market due to rising healthcare investments in the Middle Eastern countries and the growing awareness of cardiac health in Africa. The APAC region represents a promising market for cardiac point of care testing, with expectations for the highest growth rate in comparison to the Americas and EMEA. This is attributed to the vast population base, rapidly developing healthcare infrastructure in countries including China and India, and an increase in healthcare spending. Additionally, the region is experiencing a rise in lifestyle-related diseases, including heart conditions, which further propels the demand for quick and efficient diagnostic methods.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cardiac Point of Care Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing incidences of cardiovascular disorders among the population
      • Favorable government initiatives for the introduction of POC testing
      • Improving healthcare expenditure across economies worldwide
    • Market Restraints
      • Fluctuating cost of materials and components used in cardiac POC testing
    • Market Opportunities
      • Improvements and continuous advancements in cardiac POC testing
      • Advances in the development of new biomarkers to improve testing capabilities
    • Market Challenges
      • Operational and technical complexities in cardiac POC testing
  • Market Segmentation Analysis
    • Product: Increasing demand for multiplex assays across clinics
    • Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
    • End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Point of Care Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Point of Care Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Hipro Point-of-Care Diagnostics Launched in India

Analyzers are instruments used to detect the presence and concentration of cardiac biomarkers, such as troponin, B-type natriuretic peptide (BNP), and other substances indicative of cardiovascular diseases. The need for analyzers arises when immediate results are critical for diagnosing and managing cardiac conditions, particularly in emergency settings. [Published On: 2023-04-22]

Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease

Jana Care Inc. partnered with Roche Diagnostics, to develop and distribute a blood testing platform to enhance remote care for patients with chronic kidney and heart disease. The initial phase of this collaborative effort spotlights the management and surveillance of chronic conditions, specifically chronic kidney disease and heart failure. Aimed at bridging gaps created by geographical and socio-economic barriers, this platform is poised to enhance early detection and consistent monitoring, thereby optimizing the management and mitigation of disease progression. [Published On: 2023-01-30]

Cipla expands diagnostics portfolio, launches point-of-care testing device

Cipla Limited has broadened its position in diagnostics with the rollout of Cippoint, a cutting-edge point-of-care testing device. This versatile innovation is engineered to facilitate an expansive array of diagnostic evaluations encompassing cardiac markers, making it particularly vital for rapid cardiac care. Additionally, it serves a multifunctional purpose by enabling the testing for diabetes, a variety of infectious diseases, fertility concerns, thyroid irregularities, inflammation, metabolic markers, and coagulation profiles. [Published On: 2023-01-18]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Point of Care Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Point of Care Testing Market, highlighting leading vendors and their innovative profiles. These include Abaxis, Inc. by Zoetis Inc, Abbott Laboratories, ACON Laboratories, Inc., Beckman Coulter, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardiac Insight Inc., CardioGenics Holdings Inc., Chembio Diagnostic Systems, Inc. by Biosynex, EKF Diagnostics, F. Hoffmann-La Roche Ltd., Fujirebio, Horiba, Ltd., I-Sens Inc., LifeSign LLC, Nexus Dx, Inc. by Sinocare, Nova Biomedical, PTS Diagnostics by Danaher Corporation, Quidel Corporation, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trividia Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiac Point of Care Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Analyzers
    • Kits & Assays
    • Software & Services
  • Biomarker Type
    • Cardiac Troponins
    • CK-MB Fraction
    • D-Dimer
    • Heart-Type Fatty Acid-Binding Protein (H-FABP)
    • Homocysteine
    • hs C-reactive Protein (CRP)
    • Ischemia-Modified Albumin (IMA)
    • Myoglobin
    • Natriuretic Peptides (NPs)
      • Atrial Natriuretic Peptide (ANP)
      • B-type Natriuretic Peptide (BNP)
      • N-terminal proBNP (NT-proBNP)
    • sCD40L
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of cardiovascular disorders among the population
      • 5.1.1.2. Favorable government initiatives for the introduction of POC testing
      • 5.1.1.3. Improving healthcare expenditure across economies worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of materials and components used in cardiac POC testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements and continuous advancements in cardiac POC testing
      • 5.1.3.2. Advances in the development of new biomarkers to improve testing capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Operational and technical complexities in cardiac POC testing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing demand for multiplex assays across clinics
    • 5.2.2. Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
    • 5.2.3. End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cardiac Point of Care Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzers
  • 6.3. Kits & Assays
  • 6.4. Software & Services

7. Cardiac Point of Care Testing Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Cardiac Troponins
  • 7.3. CK-MB Fraction
  • 7.4. D-Dimer
  • 7.5. Heart-Type Fatty Acid-Binding Protein (H-FABP)
  • 7.6. Homocysteine
  • 7.7. hs C-reactive Protein (CRP)
  • 7.8. Ischemia-Modified Albumin (IMA)
  • 7.9. Myoglobin
  • 7.10. Natriuretic Peptides (NPs)
  • 7.11. sCD40L

8. Cardiac Point of Care Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals & Clinics
  • 8.4. Research & Academic Institutes

9. Americas Cardiac Point of Care Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cardiac Point of Care Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cardiac Point of Care Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Hipro Point-of-Care Diagnostics Launched in India
    • 12.3.2. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
    • 12.3.3. Cipla expands diagnostics portfolio, launches point-of-care testing device
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CARDIAC POINT OF CARE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CARDIAC POINT OF CARE TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 125. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 128. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 129. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 133. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 136. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 137. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 141. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 149. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 189. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 223. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 231. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 263. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 271. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 274. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 275. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 287. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 295. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 303. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2023 (USD MILLION)
  • TABLE 306. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2024-2030 (U